Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top – Investor’s Business Daily


Investor’s Business Daily
Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top
Investor’s Business Daily
Amgen (AMGN) stock toppled in after-hours trading Wednesday after reporting first-quarter sales that missed by $100 million on increased competition for two key drugs in its arsenal — immunosuppressant Enbrel and bone marrow stimulant Neupogen.
New Cholesterol Drug Falls Short as Sales Driver for AmgenBloomberg
Amgen shares fall after quarterly sales miss expectationsFinancial Times

all 3 news articles >>

Source: sales – Google News

Sharing information is key – bizEcentre Business UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd